Sale Alert!

Check out our latest deals! NEOPAR«


  Home > Equine Direct > EQ Prescriptions / RX > EQ Prescription A-C > Prescription EQ (A) >

  AnaSed Injectable
AnaSed Injectable
AnaSed Injectable


 
Rx Required  / Vet Prescription Form will be needed to send this item.
At Check Out, Please choose your method of submission for your Prescription Product
Xylazine sterile solution. Sedative, analgesic, muscle relaxant and pre-anesthetic. 100 mg/mL for use in horses and Cervidae

Item# Item Name Our Price Qty Add
288-VMAS100 AnaSed Injectable 100mg/ml 50ml
$32.79
Check the items you wish to purchase, then click


Extended Information:

ANASED«100 INJECTABLE

Rx 

Lloyd

(Xylazine)

100 mg/mL Injectable

NADA #139-236, Approved by FDA

Sedative and Analgesic for Use in Horses and Cervidae (Fallow Deer, Mule Deer, Sika Deer, White-Tailed Deer and Elk)

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION: AnaSed« is supplied in 50 mL multiple-dose vials as a sterile solution.

EACH ML CONTAINS: Xylazine hydrochloride equivalent to 100 mg of base activity, methylparaben 0.9 mg, propylparaben 0.1 mg, sodium citrate dihydrate 5.0 mg and water for injection. pH adjusted with citric acid and sodium citrate.

Protect from heat. Do not store over 30║C (86║ F).

PHARMACOLOGY: Xylazine, a non-narcotic compound, is a sedative and analgesic as well as a muscle relaxant. Its sedative and analgesic activity is related to central nervous system depression. Its muscle-relaxant effect is based on inhibition of the intraneural transmission of impulses in the central nervous system. This principal pharmacological activities develop within 10 to 15 minutes after intramuscular injection in horses and Cervidae, and within 3 to 5 minutes following intravenous administration in horses.

A sleeplike state, the depth of which is dose-dependent, is usually maintained for 1 to 2 hours, while analgesia lasts from 15 to 30 minutes. The centrally acting muscle-relaxant effect causes relaxation of the skeletal musculature complementing sedation and analgesia.

In horses and Cervidae under the influence of xylazine, the respiratory rate is reduced as in natural sleep. Following treatment with xylazine, the heart rate is decreased and a transient change in the conductivity of the cardiac muscle may occur, as evidenced by a partial atrioventricular block. This resembles the atrioventricular block often observed in normal horses.1,2,3,4 Although a partial A-V block may occasionally occur following intramuscular injection of xylazine, the incidence is less than when it is administered intravenously. Intravenous administration of xylazine causes a transient rise in blood pressure, followed by a slight decrease.

Xylazine has no effect on blood clotting time or other hematologic parameters.

INDICATIONS: Xylazine should be used in horses and Cervidae (Fallow Deer, Mule Deer, Sika Deer, White-Tailed Deer and Elk) when it is desirable to produce a state of sedation accompanied by a shorter period of analgesia. Horses: Xylazine has been used successfully as follows:

1. Diagnostic procedures - oral and ophthalmic examinations, abdominal palpation, rectal palpation, vaginal examination, catheterization of the bladder and radiographic examinations.

2. Orthopedic procedures, such as application of casting materials and splints.

3. Dental procedures.

4. Minor surgical procedures of short duration such as debridement, removal of cutaneous neoplasms and suturing of lacerations.

5. To calm and facilitate handling of fractious animals.

6. Major surgical procedures:

a. When used as a preanesthetic to general anesthesia.

b. When used in conjunction with local anesthetics

Cervidae: Xylazine may be used for the following:

1. To calm and facilitate handling of fractious animals.

2. Diagnostic procedures.

3. Minor surgical procedures.

4. Therapeutic medication for sedation and relief of pain following injury or surgery.

5. As a preanesthetic to local anesthesia. AnaSed at the recommended dosages can be used in conjunction with local anesthetics, such as procaine or lidocaine.

DOSAGE AND ADMINISTRATION:

1. Dosage - Horses:

Intravenous --- 0.5 mL/100 lb body weight (0.5 mg/lb or 1.1 mg/kg).

Intramuscular --- 1.0 mL/100 lb body weight (1 mg/lb or 2.2 mg/kg).

Cervidae: Administer intramuscularly, by either hand syringe or syringe dart, in the heavy muscles of the croup or shoulder.

Fallow Deer (Dama dama) - 2.0 to 4.0 mL/100 lbs body weight (2.0 to 4.0 mg/lb or 4.4 to 8.8 mg/kg).

Mule Deer (Odocoileus hemionus) - 1.0 to 2.0 mL/100 lbs body weight (1.0 to 2.0 mg/lb or 2.2 to 4.4 mg/kg).

Sika Deer (Cervus nippon) - 1.0 to 2.0 mL/100 lbs body weight (1.0 to 2.0 mg/lb or 2.2 to 4.4 mg/kg).

White-Tailed Deer (Odocoileus virginianus) - 1.0 to 2.0 mL/100 lbs body weight (1.0 to 2.0 mg/lb or 2.2 to 4.4 mg/kg).

Elk (Cervus canadensis) - 0.25 to 0.5 mL/100 lbs body weight (0.25 to 0.5 mg/lb or 0.55 to 1.1 mg/kg).

Following injection of xylazine, the animal should be allowed to rest quietly until the full effect has been reached. These dosages produce sedation which is usually maintained for 1 to 2 hours, and analgesia which lasts for 15 to 30 minutes.

2. Preanesthetic to Local Anesthesia - Xylazine at the recommended dosages can be used in conjunction with local anesthetics, such as procaine or lidocaine.

3. Preanesthetic to General Anesthesia - Xylazine at the recommended dosage rates produces an additive effect to central nervous system depressants such as pentobarbital sodium, thiopental sodium and thiamyl sodium. Therefore, the dosage of such compounds should be reduced and administered to the desired effect. In general, only 1/3 to 1/2 of the calculated dosage of the barbiturates will be needed to produce a surgical plane of anesthesia. Post-anesthetic or emergence excitement has not been observed in animals pre-anesthetized with xylazine.

Xylazine has been used successfully as a preanesthetic agent for pentobarbital sodium, thiopental sodium, thiamylal sodium, nitrous oxide, ether, halothane, glyceryl guaiacolate and methoxyflurane anesthesia.

SIDE EFFECTS: Xylazine in horses and Cervidae used at recommended dosage levels may occasionally cause slight muscle tremors, bradycardia with partial A-V heart block and a reduced respiratory rate. Movement in response to sharp auditory stimuli may be observed. In horses, sweating, rarely profuse, has been reported following administration. In Cervidae, salivation, various vocalizations (bellowing, bleating, groaning, grunting, snoring) on expiration, audible grinding of molar teeth, protruding tongue and elevated temperatures have also been noted in some cases.

PRECAUTIONS: Careful consideration should be given before administering to horses and Cervidae with significantly depressed respiration, severe pathologic heart disease, advanced liver or kidney disease, severe endotoxic or traumatic shock and stress conditions such as extreme heat, cold, high altitude, or fatigue.

Analgesic effect is variable, and depth should be carefully assayed prior to surgical/clinical procedures. Variability of analgesia occurs most frequently at the distal extremities of horses and Cervidae. In spite of sedation, the practitioner and handlers should proceed with caution since defense reactions may not be diminished.

Intracarotid Arterial Injection Should be Avoided. As with many compounds, including tranquilizers, immediate violent seizures followed by collapse may result from inadvertent administration into the carotid artery. Although the reaction with xylazine is usually transient and recovery may be rapid and complete, special care should be taken to assure that the needle is in the jugular vein rather than the carotid artery.

Horses: Since an additive effect results from the use of xylazine and the barbiturate compounds, it should be used with caution with these central nervous system depressants. Products known to produce respiratory depression or apnea, such as thiamylal sodium should be given at a reduced dosage and, when injected intravenously, should be administered slowly. When intravenous administration is desired, avoid perivascular injection in order to achieve the desired effect. Studies have shown negligible evidence of tissue irritation, however, following perivascular injection of xylazine.

Bradycardia and an arrhythmia in the form of incomplete atrioventricular block have been reported following xylazine administration. Although clinically the importance of this effect is questioned,1,2,3,4 a standard dose of atropine given prior to or following xylazine will greatly decrease the incidence.

Sedation for transport is most successful if actual transportation is begun after the full effect of the drug has been reached and the animal's stability is maintained while standing. In addition, it should be noted that animals under the influence of xylazine can be aroused by noise or other stimuli and this may increase the risk of injury.

Cervidae: It is preferable to administer AnaSed« to fasted Cervidae. As in all ruminants, a safeguard against aspiration of food material into the lungs and/or bloat during deep sedation is necessary.

Care should be taken to administer AnaSed« in the heavy muscles of the croup or shoulder. Injections given subcutaneously, intraperitoneally or into fat deposits will give unpredictable results.

Cervidae should not be disturbed during induction or until the full effect of the drug has been reached which is usually 10 to 15 minutes following injection.

The usual time to initial effect of the drug is 2 to 5 minutes. The administrator of the drug should be fully cognizant of this interval prior to administration of drug to free-ranging deer or elk, especially at night or in heavily wooded areas.

If the animal has been underdosed (faulty injection or miscalculation on weight), it is advisable to wait one hour before administering a second dose.

Adequate ventilation-especially in cages or crates-is mandatory; keep head and neck in position to ensure patient air passage and to prevent aspiration of stomach contents.

During sedation, Cervidae should be prevented from assuming lateral recumbency. A sternal recumbent position is desirable.

While under the effects of xylazine, the animal should be protected from an extremely hot or cold environment.

Efforts should be made to prevent patient from rising until almost complete recovery is attained.

The transportation of Cervidae given AnaSed« should be carefully monitored to prevent excessive struggling, injury or death.

Hyperthermic reactions may occur, especially if the subject is in a highly excited psychic state when the drug is administered. Hosing the head and entire body with cold water has usually proven to be an effective deterrent.

Data are presently inadequate to recommend AnaSed«'s use in pregnant Cervidae. Avoid use during breeding season.

Cervidae should be observed closely until all of the sedative effects of XYLAZINE HCL are gone.

Care should be taken at all times when administering AnaSed« to Cervidae. This is due to the method of administration (usually darting), the difficulty in estimating body weights and the accepted theory that wild animals are more unpredictable in their response to sedatives and analgesics than the domesticated species.

SAFETY: Xylazine has been tested in horses at 5 times the recommended dose, and at doses above the recommended range in Cervidae. However, doses of this magnitude may produce convulsions and long periods of sedation in horses and muscle tremors and long periods of sedation in Cervidae.

WARNING: The drug is for use in horses and Cervidae only and should not be administered to food-producing animals.

Avoid accidental administration to humans. Should such exposure occur, notify a physician immediately. Artificial respiration may be indicated.

In Cervidae, occasional capture-associated deaths occur. Clinical trials reveal a mortality rate of approximately 3.5% attendant with the administration of xylazine.

REFERENCES:

1. Detweiler, D.K.: The Diagnosis and Significance of Cardiac Arrhythmias in Progress in Equine Practice. Edited by E.J. Catcott and J.F. Smithcors. American Veterinary Publications, Inc., Santa Barbara, California and Wheaton, Illinois, (1966), 280-281.

2. Glazier, D.B.: Atrioventricular Heart Block. Irish Vet. J., Vol. 12, (1958), 194-198.

3. Holmes, J.R., Alps, B.J.: Observations on Partial Atrioventricular Heart Block in the Horse. Can. Vet. J., Vol. 7, No. 12, (1966), 280-290.

4. Smetzer, D.L., Smith, C.R., Senta, T.: Second Degree Atrioventricular Block in the Horse. Am. J. Vet. Res., Vol. 30, No. 6, (1969), 933-946.

Manufactured by: Ben Venue Laboratories, Inc., Bedford, Ohio 44146

July, 1995

Manufactured for LLOYD Laboratories, div. of LLOYD, Inc., Shenandoah, Iowa 51601 U.S.A.

U.S. Pat. No. 4,614,798

NAC No.: 11350000
 

ANASED«20 INJECTION

 
Rx
 
Lloyd

Xylazine Sterile Solution-Sedative and Analgesic

20 mg/mL

For Use in Dogs and Cats Only

NADA 139-236, Approved by FDA

DESCRIPTION: AnaSed« is supplied as a sterile solution. Each mL contains xylazine hydrochloride equivalent to 20 mg base activity, methylparaben 0.9 mg, propylparaben 0.1 mg, and water for injection. pH adjusted with citric acid and sodium citrate.

PHARMACOLOGY: Xylazine, a nonnarcotic compound, is a sedative and analgesic as well as a muscle relaxant.1 Its sedative and analgesic activity is related to central nervous system depression. Its muscle relaxant effect is based upon inhibition of the intraneural transmission of impulses in the central nervous system. The principal pharmacological activities develop within 10 to 15 minutes after intramuscular or subcutaneous injection, and within three to five minutes following intravenous administration.

A sleeplike state, the depth of which is dose-dependent, is usually maintained for one to two hours, while analgesia lasts from 15 to 30 minutes. The centrally acting muscle relaxant effect causes relaxation of the skeletal musculature complementing sedation and analgesia.

In animals under the influence of xylazine, the respiratory rate is reduced as in natural sleep. Following treatment with xylazine, the heart rate is decreased and a transient change in the conductivity of the cardiac muscle may occur as evidenced by a partial atrioventricular block. This resembles the atrioventricular block often observed in apparently normal animals.2 Intravenous administration of xylazine causes a transient rise in blood pressure, followed by a slight decrease.

Xylazine does not have an effect on blood clotting time or other hematologic parameters.

Indications: Xylazine should be used in dogs and cats when it is desirable to produce a state of sedation accompanied by a shorter period of analgesia. Xylazine has been used successfully as follows:

1. Diagnostic procedures - examination of mouth and ears, abdominal palpation, rectal palpation, vaginal examination, catheterization of the bladder and radiographic examinations of the head and extremities.

2. Orthopedic procedures, such as application of casting materials and splints.

3. Dental procedures.

4. Minor surgical procedures of short duration such as debridement, removal of cutaneous neoplasms and suturing of lacerations.

5. To calm and facilitate the handling of fractious animals.

6. Major surgical procedures:

a. Used as a pre-anesthetic to general anesthesia.

b. Used in conjunction with local anesthetics.

DOSAGE AND ADMINISTRATION:

1. Dosage - Intravenous - 0.5 mL/20 lbs body weight (0.5 mg/lb, or 1.1 mg/kg).

Intramuscular or subcutaneous - 1.0 mL/20 lbs body weight (1.0 mg/lb or 2.2 mg/kg).

In large dogs (over 50 lbs) a dosage of 0.5 mg/lb administered intramuscularly may provide sufficient sedation and/or analgesia for most procedures.

Since vomiting may occur (see SIDE EFFECTS), fasting for 6-24 hours prior to the use of xylazine may reduce the incidence; the I.V. route results in the least vomiting.

Following the injection of xylazine, the animal should be allowed to rest quietly until the full effect has been reached.

These dosages produce sedation which is usually maintained for 1 to 2 hours and analgesia which lasts for 15 to 30 minutes.

2. Pre-anesthetic to local anesthesia: Xylazine at the recommended dosages can be used in conjunction with local anesthetics, such as procaine or lidocaine.

3. Pre-anesthetic to general anesthesia: Xylazine, at the recommended dosage rates, produces an additive effect to central nervous system depressants such as pentobarbital sodium, thiopental sodium and thiamylal sodium. Therefore, the dosage of such compounds should be reduced and administered to the desired effect. In general, 1/3 to 1/2 of the calculated dosage of the barbiturates will be needed to produce a surgical plane of anesthesia. Postanesthetic or emergence excitement has not been observed in animals pre-anesthetized with xylazine.

Xylazine has been used successfully as a pre-anesthetic agent for pentobarbital sodium, thiopental sodium, thiamylal sodium, nitrous oxide, ether, halothane and methoxyflurane anesthesia.

SIDE EFFECTS: Emesis occurs occasionally in dogs, and frequently in cats, soon after the administration of xylazine, but before clinical sedation is evident. When observed, emesis usually occurs only a single time, after which there is no further emetic effect. The use of anti-emetics may delay this phenomenon. The occurrence of emesis may be considered a desirable effect when xylazine is administered as a pre-anesthetic to general anesthesia.

Xylazine used at the recommended dosage levels may occasionally cause slight muscle tremors, bradycardia with partial A-V heart block and a reduced respiratory rate. Should excessive respiratory depression or bradycardia occur following the use of AnaSed (xylazine), administer yohimbine to rapidly reverse the xylazine-induced effects.

Gaseous extension of the stomach may occur in dogs treated with xylazine making radiographic interpretation more difficult.3

Movement in response to sharp auditory stimuli may be observed.

Increased urination may occur in cats following the use of xylazine.

PRECAUTIONS:

Clinical results with xylazine have not revealed any detrimental effects when the compound is administered to pregnant dogs or cats. However, until more definitive studies are completed, xylazine is not recommended for use in these animals.

Careful consideration should be given before administering to dogs or cats with significantly depressed respiration, severe pathologic heart disease, advanced liver or kidney disease, severe endotoxic or traumatic shock and stress conditions such as extreme heat, cold, or fatigue.

Analgesic effect is variable, and depth should be carefully assayed prior to surgical/clinical procedures. In spite of sedation, the practitioner and handlers should proceed with caution since defense reactions may not be diminished.

Do not use xylazine in conjunction with tranquilizers.

Since an additive effect results from the use of xylazine and the barbiturate compounds, it should be used with caution with these central nervous system depressants. Products known to produce respiratory depression or apnea, such as thiamylal sodium, should be given at a reduced dosage and, when injected intravenously, should be administered slowly.

When intravenous administration is desired, avoid perivascular injection in order to achieve the desired effect. Studies have shown negligible evidence of tissue irritation, however, following the perivascular injection of xylazine.

Bradycardia and an arrhythmia in the form of incomplete atrioventricular block have been reported following xylazine administration. Although clinically the importance of this effect is questioned, a standard dose of atropine given prior to or following xylazine will greatly decrease the incidence.

While sedation usually lasts from 1 to 2 hours, recovery periods in excess of 4 to 5 hours have been reported in dogs and cats.

SAFETY: Xylazine has been tested in dogs at 4 times the recommended dose. Doses of this magnitude produced muscle tremors, emesis and long periods of sedation.4

WARNING: The drug is for use in dogs and cats only.

STORAGE: Protect from heat. Do not store over 30░C (86░F).

HOW SUPPLIED: 20 mL multiple-dose vials containing 20 mg base activity per mL, List No. 4811.

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

REFERENCES:

1. Upson, D.W.: Upson's Handbook of Clinical Veterinary Pharmacology. VM Publishing, Inc., Bonner Springs, Kansas, (1981), 148, 248.

2. Detweiler, D.K, Patterson, D.F., Luginbuhl, H., Rhodes, W.H., Buchanan, J.W., Knight, D.H., Hill, J.D.: Diseases of the Cardiovascular System in Canine Medicine, Edited by E.J. Catcott, American Veterinary Publications, Inc. Santa Barbara, California and Wheaton, Illinois, (1968), 589-679.

3. Bargai U.: The effect of xylazine hydrochloride on the radiographic appearance of the stomach and intestine in the dog. Vet. Radio. 23:60-63, 1982.

4. VET-A MIX Research.

February, 1996

Manufactured by Ben Venue Laboratories, Inc., Bedford, Ohio 44146

Manufactured for LLOYD Laboratories, Shenandoah, Iowa 51601 U.S.A.

NAC No.: 11350010




Share your knowledge of this product with other customers... Be the first to write a review

Browse for more products in the same category as this item:

Equine Direct > EQ Prescriptions / RX > EQ Prescription A-C > Prescription EQ (A)
Farm Direct > Farm Prescriptions / RX Drugs > Farm Script A-C > Farm Script (A)
Pet Direct > Pet Prescription Drugs > Pet RX A-C > Pet RX (A)
Breeder Direct > Prescriptions / RX > Prescriptions A - C > Prescriptions (A)

A to Z Vet Supply is upfront HACKER SAFE certified sites prevent over 99.9% of hacker crime.
Click for the BBB Business Review of this Veterinarians Equipment & Supplies in Dresden TN






Google+
Social Tab
Are you a fan of A to Z Vet Supply?
Hide Bar

Read our latest blog post...